Fortrea Holdings (FTRE) Gains from Investment Securities (2022 - 2026)
Fortrea Holdings (FTRE) reported Gains from Investment Securities of -$400000.0 for Q1 2026, down 33.33% on a YoY basis from -$600000.0 in Q1 2025, and up 82.61% quarter-over-quarter from -$2.3 million in Q4 2025.
Fortrea Holdings (FTRE) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Gains from Investment Securities for 5 years, with the latest figure at -$400000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 33.33% year-over-year to -$400000.0; the trailing twelve-month figure through Mar 2026 stood at -$4.6 million (down 330.0% YoY), and the FY2025 full-year result was -$4.5 million, down 131.25% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$400000.0, up from -$2.3 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $19.1 million in Q4 2024, with the low at -$12.5 million in Q3 2024.
- Historically, Gains from Investment Securities has averaged $853333.3 across 5 years, with a median of -$300000.0 in 2025.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 3100.0% — and 2024, when it tumbled 516.67%.
- Fortrea Holdings' Gains from Investment Securities stood at $3.4 million in 2022, then increased by 2.94% to $3.5 million in 2023, then surged by 445.71% to $19.1 million in 2024, then plunged by 112.04% to -$2.3 million in 2025, then jumped by 82.61% to -$400000.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$400000.0 (Q1 2026), -$2.3 million (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -400,000.00 |
| Mar 31, 2026 | -400,000.00 |
| Dec 31, 2025 | -2.30 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -2.00 Mn |
| Mar 31, 2025 | -300,000.00 |
| Mar 31, 2025 | -300,000.00 |
| Dec 31, 2024 | 19.10 Mn |
| Dec 31, 2024 | 19.10 Mn |
| Sep 30, 2024 | -12.50 Mn |
| Sep 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -4.30 Mn |
| Jun 30, 2024 | -4.30 Mn |
| Mar 31, 2024 | 12.10 Mn |
| Mar 31, 2024 | 12.10 Mn |
| Dec 31, 2023 | 3.50 Mn |
| Dec 31, 2023 | 3.50 Mn |